Innoviva Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: South San Francisco CA United States (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
None
First Marketed Drug
2023
sulbactam (unasyn)
First NDA Approval
2023
durlobactam (Xacduro)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (2)

Key: Innoviva (1) Acquired (1)

durlobactam (Xacduro) (2023 NDA)

sulbactam (unasyn) (2023)

Drugs in Phase 3 Trials (5)

Key: Innoviva (0) Acquired (5)

cilastatin (primaxin) (3 trials)

colistin (1 trial)

etx2514 (5 trials)

imipenem (primaxin) (3 trials)

sulbactam (unasyn) (5 trials)

Drugs in Phase 1 Trials (4)

Key: Innoviva (0) Acquired (4)

cefpodoxime (vantin) (1 trial)

etx0282 (1 trial)

moxifloxacin (avelox) (1 trial)

zoliflodacin (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 9
  • # of Trial APIs: 9